Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera

Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera

Published 2 months, 3 weeks ago
Description
A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike major licensing deals with SK Biopharmaceuticals and Sentivera, and Raviv Pryluk makes the case for rethinking clinical trial sample sizing.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us